Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab, Nivolumab, and Cabozantinib in anti-PD-1 refractory cutaneous melanoma
NCT05200143Phase 2Terminated
- Start
- Jun 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in cutaneous melanoma (CM). Started Jun 2022; status: terminated.
02
Drugs
cabozantinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT05200143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05200143.